Therapeutic decision making in BMT/SCT for non–Hodgkin lymphoma

Disease classification page 100 Disease staging 101 Immune phenotype of lymphoid neoplasms, cytogenetic, and molecular abnormalities 101 Prognostic factors for outcome with conventional therapy 102 Results with conventional therapy 105 CHOP chemotherapy plus rituximab compared with Chop alone in elderly patients with diffuse large B-cell lymphoma 106 Approach to HIV-related non–Hodgkin lymphomas 108 Results with autologous transplant 109 CIBMTR data 113 Probability of survival after autotransplants 113 Secondary malignancy after autologous transplant 116 Results with allogeneic transplant 116 Indications for autologous transplant 119 Indications for allogeneic transplant 119 Contraindications to autologous transplant 119 Pretransplant workup 119 Posttransplant radiotherapy protocol 120 Monitoring posttransplant 121 Further reading 122 Addenda: Treatment algorithms 124 Treatment recommendations for aggressive lymphoma (excluding Burkitt and lymphoblastic lymphoma) 124 Diffuse large B-cell lymphoma 124 Mantle cell lymphoma 124 Primary mediastinal B-cell lymphoma 124 T-cell lymphoma 125 Treatment algorithms for relapsed follicular lymphoma and relapsed/refractory aggressive NHL 125 Disease classification Disease staging Ann Arbor classification (Carbone et al., 1971): Stage I: Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (IE) Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of an extralymphatic organ or site and of one or more lymph node regions on the same side of the diaphragm (IIE) Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE) or the spleen (IIIS) or both (IIISE) […